SEC Company Response from TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686) (TEVA) — Apr 16, 2018
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA, TEVJF) (CIK 0000818686)
Date: April 16, 2018 · CIK: 0000818686 · Accession: 0001193125-18-118591
AI Filing Summary & Sentiment
Letter
Acceleration Request
Teva Pharmaceutical Industries Limited
5 Basel Street
P.O. Box
Petach Tikva, 4951033 Israel
April 16, 2018
Via EDGAR Submission
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549 3628
Attention: Filing Desk
Re: Teva Pharmaceutical Industries Limited
Registration Statement on Form S-3
SEC File No. 333- 222767
Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Teva Pharmaceutical Industries Limited (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 222767), as amended by the Amendment No. 1 filed on February 16, 2018 and as amended by the Amendment No. 2 filed on March 28, 2018 (together, the “Registration Statement”), to 8:00 a.m. Eastern Time, on Thursday, April 19, 2018 or as soon thereafter as practicable. The Company hereby acknowledges its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement.
* * * *
Securities and Exchange Commission
April 16, 2018
Page
Please contact Ross M. Leff of Kirkland & Ellis LLP, special counsel to the Company, at (212) 446-4947, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Sincerely,
Teva Pharmaceutical Industries Limited
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Teva Pharmaceutical Industries Limited 5 Basel Street P.O. Box 3190 Petach Tikva, 4951033 Israel April 16, 2018 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 3628 Attention: Filing Desk Re: Teva Pharmaceutical Industries Limited Registration Statement on Form S-3 SEC File No. 333- 222767 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Teva Pharmaceutical Industries Limited (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333- 222767), as amended by the Amendment No. 1 filed on February 16, 2018 and as amended by the Amendment No. 2 filed on March 28, 2018 (together, the “Registration Statement”), to 8:00 a.m. Eastern Time, on Thursday, April 19, 2018 or as soon thereafter as practicable. The Company hereby acknowledges its responsibilities under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement. * * * * Securities and Exchange Commission April 16, 2018 Page 2 Please contact Ross M. Leff of Kirkland & Ellis LLP, special counsel to the Company, at (212) 446-4947, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter. Sincerely, Teva Pharmaceutical Industries Limited By: /s/ Deborah Griffin Name: Deborah Griffin Title: Senior Vice President and Chief Accounting Officer Teva Pharmaceutical Finance IV, LLC By: /s/ Deborah Griffin Name: Deborah Griffin Title: President, Chief Executive Officer and Manager Teva Pharmaceutical Finance V, LLC By: /s/ Deborah Griffin Name: Deborah Griffin Title: President, Chief Executive Officer and Manager Teva Pharmaceutical Finance VI, LLC By: /s/ Deborah Griffin Name: Deborah Griffin Title: President, Chief Executive Officer and Manager Teva Pharmaceutical Finance Company B.V. By: Teva Pharmaceutical Finance Netherlands III B.V., its Managing Director By: Teva Pharmaceuticals Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director Teva Pharmaceutical Finance IV B.V. By: Teva Pharmaceutical Finance Netherlands II B.V., its Managing Director By: Teva Pharmaceuticals Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director Teva Pharmaceutical Finance V B.V. By: Teva Pharmaceutical Finance Netherlands IV B.V., its Managing Director By: Teva Pharmaceuticals Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director Teva Pharmaceutical Finance N.V. By: /s/ Iseline Gouverneur Name: Iseline Gouverneur Title: Managing Director A By: /s/ Doron Herman Name: Doron Herman Title: Managing Director B Teva Pharmaceutical Finance Netherlands II B.V. By: Teva Pharmaceutical Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director Teva Pharmaceutical Finance Netherlands III B.V. By: Teva Pharmaceutical Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director Teva Pharmaceutical Finance Netherlands IV B.V. By: Teva Pharmaceutical Europe B.V., its Managing Director By: /s/ David Vrhovec Name: David Vrhovec Title: Managing Director By: /s/ John Nason Name: John Nason Title: Managing Director cc: Ross M. Leff Kirkland & Ellis LLP